Details checkedStrong evidenceCheckedregulatory

PEDMARK by Fennec Pharmaceuticals

Also known as: PEDMARK, PEDMARQSI, sodium thiosulfate injection

Fennec Pharmaceuticals

Primary source

Company

Fennec Pharmaceuticals

Program Type

Therapeutic

Modality

Small Molecule

Stage

Marketed

Status

Marketed

Target Gene

—

Route / Mode

Intravenous

Confidence

98%

Status Confidence

Status confirmed

Evidence Strength

Strong evidence

Last Reviewed

2026-05-31

Geography

United States, European Union, United Kingdom

Population

pediatric, cisplatin-ototoxicity

Trial IDs

Mechanism

Systemic sodium thiosulfate reduces cisplatin-associated ototoxicity by chemically inactivating reactive platinum species after chemotherapy.

Indications

Cisplatin-Induced Hearing Loss Hearing Loss

Notes

Only clearly commercialized hearing-loss-prevention drug in this set; marketed in the U.S. as PEDMARK and in Europe/UK as PEDMARQSI.

Evidence & Sources

3 structured sources

regulatory

Supports: canonicalName, company, stage, status, indications, route

IDs: PEDMARK

Open

regulatory

Supports: route, populationTags, notes

IDs: 212937

Open

company

Supports: aliases, geography, allCompanies

IDs: PEDMARQSI

Open

Key Events

2022-09-20

FDA approved PEDMARK for cisplatin-associated ototoxicity risk reduction in pediatric patients

Related Programs

Otarmeni by Regeneron

Company: Regeneron Pharmaceuticals · Gene Therapy · Approved

AK-OTOF by Eli Lilly and Akouos

Company: Eli Lilly and Company · Gene Therapy · Phase 2

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

SENS-501 by Sensorion

Company: Sensorion · Gene Therapy · Phase 1/2

Rincell-1 by Rinri Therapeutics

Company: Rinri Therapeutics · Cell Therapy · Phase 1/2

AC102 by AudioCure Pharma

Company: AudioCure Pharma · Small Molecule · Phase 2